ReviewCancer gene therapy2025
PANoptosis in cancer: molecular mechanisms and therapeutic potential.
Review in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- PANoptosis in the pathogenesis of myelodysplastic syndromes.Molecular oncology · 2026Review
- ABT-737 efficiently inhibits hepatocellular carcinoma cell activity via regulating PANoptosis.Discover oncology · 2026Article
- NLRP12 in cancer: a context-dependent regulator of tumor progression, immunity, and metabolism.Frontiers in oncology · 2026Review
- Emerging role of PANoptosis in pathogen infection and systemic diseases.Cell biology and toxicology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumorigenesis is closely related to an imbalance in cell death regulation. PANoptosis is a recently characterized form of programmed cell death that integrates the molecular features of cellular pyroptosis, apoptosis and necrotic apoptosis through the assembly of a multiprotein complex termed the PANoptosome. Beyond its role in cancer initiation and progression, PANoptosis is intricately linked to immune responses within the tumor microenvironment, thus offering new avenues for therapeutic intervention. The present review outlines the interplay among different cell death pathways, highlights the defining characteristics and assembly mechanisms of PANoptosis, as well as discusses its functional roles in cancer biology. Additionally, the implications of PANoptosis in tumor immunity and the potential of targeting this pathway in cancer therapy are explored.
Indexed as
Identifiers
40841819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.